Spero Therapeutics, Inc.
NASDAQ:SPROBiotechnology
+$0.08 today
- Market cap
- $50.92M
- Beta
- 1.46
- P/E (TTM)
- 8.2
- EPS (TTM)
- $0.27
Volume 0.27M
Average 0.78M
SPRO Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Spero Therapeutics, Inc.NASDAQ: SPRO
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) grows in line with its trailing trend
Q1 FY2026 weighted avg shares (diluted) of 57.28M shares rose 3.4% year over year, behind the +5.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 3.5% from the prior quarter. Over 3 fiscal years it compounded at +16.2% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +3.4% toward the trailing-twelve-month pace of +5.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 59.04M USD
- Year-over-year change
- +9.3%
- 4-year CAGR
- +17.6%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 59.04M | +9.3% |
| FY2024 | 2024-12-31 | 54.04M | +2.0% |
| FY2023 | 2023-12-31 | 52.99M | +41.0% |
| FY2022 | 2022-12-31 | 37.59M | +21.7% |
| FY2021 | 2021-12-31 | 30.9M | — |
Weighted Avg Shares (Diluted) vs competitors
How SPRO compares with its peers on the latest reported figures
- SPRO's LTM Mar 2026 weighted avg shares (diluted) of 57.24M shares is the 5th highest of the 10 companies compared; the peer median is 56.96M shares.
- Its year-over-year change of +5.3% is the 8th highest of 10, against a peer median of +30.5%.
- Over three fiscal years its annual growth of +16.2% compares with a peer median of +35.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
IRDOpus Genetics, Inc. | LTM Mar 2026 | 406.29M | +1283.9% | +211.4% |
| LTM Mar 2026 | 312.72M | +1040.7% | +186.8% | |
| LTM Mar 2026 | 79.93M | +69.4% | +35.9% | |
| LTM Mar 2026 | 61.23M | +1.8% | +14.3% | |
| LTM Mar 2026 | 57.24M | +5.3% | +16.2% | |
| LTM Mar 2026 | 56.96M | -7.5% | -2.7% | |
| LTM Mar 2026 | 50.79M | +127.0% | +911.7% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | 21.96M | +12.5% | +11.8% |
| LTM Mar 2026 | 12.8M | +30.5% | +47.3% | |
| LTM Mar 2026 | 8.99M | +10.4% | +18.0% | |
| Peer median (excluding SPRO) | 56.96M | +30.5% | +35.9% | |
Competitors are the stored peer set for SPRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.07M | 48.58M | 103.78M | 47.98M | 59.62M |
| Cost of Revenue | 0 | 0 | 51.44M | 96.76M | 0 |
| Gross Profit | 3.07M | 48.58M | 52.34M | (48.78M) | 59.62M |
| Gross Margin | 100.0% | 100.0% | 50.4% | -101.7% | 100.0% |
| Research & Development | 64.53M | 47.59M | 51.44M | 96.76M | 38.47M |
| Selling, General & Admin | 41.7M | 36.48M | 25.55M | 23.7M | 21.18M |
| Operating Expenses | 91.04M | 90.78M | 30.86M | 24.58M | 59.64M |
| Depreciation & Amortization | 646K | 869K | 367K | 2K | 0 |
| EBITDA | (87.17M) | (42.94M) | 27.15M | (72.48M) | 8.83M |
| EBITDA Margin | -2839.4% | -88.4% | 26.2% | -151.1% | 14.8% |
| Operating Income | (87.97M) | (42.2M) | 21.48M | (73.36M) | (24K) |
| Operating Margin | -2865.5% | -86.9% | 20.7% | -152.9% | -0.0% |
| Interest Income | 346K | 1.11M | 3.94M | 4.74M | 2.51M |
| Interest Expense | 1.94M | 2.61M | 0 | 0 | 0 |
| Other Income / Expenses | (1.79M) | (4.22M) | 3.92M | 4.8M | 8.86M |
| Income Before Tax | (89.76M) | (46.42M) | 25.4M | (68.57M) | 8.83M |
| Pre-Tax Margin | -2923.6% | -95.5% | 24.5% | -142.9% | 14.8% |
| Income Tax Expense | 0 | 0 | 2.6M | 0 | 261K |
| Net Income | (89.76M) | (46.42M) | 22.81M | (68.57M) | 8.57M |
| Net Margin | -2923.6% | -95.5% | 22.0% | -142.9% | 14.4% |
| EPS (Basic) | (2.91) | (1.23) | 0.43 | (1.27) | 0.15 |
| EPS (Diluted) | (2.91) | (1.23) | 0.43 | (1.27) | 0.15 |
| Weighted Avg Shares | 30.9M | 37.59M | 52.7M | 54.04M | 56.02M |
| Weighted Avg Shares (Diluted) | 30.9M | 37.59M | 52.99M | 54.04M | 59.04M |
Spero Therapeutics, Inc.
NASDAQ:SPRO
Intrinsic Alpha fair value
Locked
Current Price
$0.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.